Oncology
1 drug is in development for Pancreatic Neoplasms.
- Companies
- 1
- Clinical trials
- 5
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Pancreatic Neoplasms pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| tc-510 | TCR2 THERAPEUTICS INC. (TCRR) |
About this indication
Pancreatic Neoplasms context
Oncology·MeSH: Pancreatic Neoplasms (D010190)
Also known as: Neoplasm, Pancreas, Neoplasm, Pancreatic, Neoplasms, Pancreas
Narrower concepts tracked separately: Pancreas Cancer, Pancreatic Carcinoma, Cancer of the Pancreas, Pancreatic Cancer
Prevalence
8.0 / 100K
Incidence
13.1 / 100K/yr
Frequently asked questions
How many drugs are in development for Pancreatic Neoplasms?
BioSniper tracks 1 drug in development for Pancreatic Neoplasms across 1 company.
How many clinical trials target Pancreatic Neoplasms?
There are 5 clinical trials targeting Pancreatic Neoplasms tracked by BioSniper.
What is the prevalence of Pancreatic Neoplasms?
The estimated prevalence of Pancreatic Neoplasms is approximately 8.0 per 100,000 population.